EMA Issues Guideline on Fast Tracking Drugs for Unmet Needs
EMA’s revised guideline on the implementation of accelerated assessment is open for public consultation.
The European Medicines Agency (EMA) announced on July 27, 2015 that it has revised its guideline on the implementation of accelerated assessment and conditional marketing authorization to improve existing framework. These guidelines are part of European legislation targeting the acceleration of patient access to innovative therapies.
Changes to the guidelines regarding accelerated assessment include information on how to justify the fulfillment of a major public health threat, optimization of the assessment timetable, and an emphasis on early communication with EMA.
In regards to conditional marketing authorization, the revised guideline also emphasizes the importance of early communication and planning. The revised guideline includes:
- Explanation on fulfillment of unmet medical needs
- “Clarification of how a positive benefit-risk balance is to be substantiated where there are less complete data, with further guidance on the level of evidence that must be provided at the time of authorization and the data that can be provided after authorization”
- Clarification on the extent and type of data required for annual renewal submissions.
The revisions came after experience the agency gained from the implantation of accelerated assessment and marketing authorization in the past [How many?] years as well as discussions with the European Commission Expert Group on Safe and Timely Access to Medicines for patients.
Public consultation on the revised guidelines is open until Sept. 30, 2015.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
